Literature DB >> 34032887

[Pain in multiple sclerosis and neuromyelitis optica spectrum disorders].

Hannah L Pellkofer1, Tania Kümpfel2.   

Abstract

Multiple sclerosis and neuromyelitis optica spectrum disorders are autoimmune inflammatory diseases of the central nervous system, which can lead to a multitude of neurological complaints and pain syndromes. Pain may be an acute symptom during disease exacerbation as well as a chronic symptom, whereby the latter sometimes substantially reduces the quality of life. The etiology of pain is very heterogeneous but the rapid differential diagnostic classification is decisive in order to be able to initiate a differentiated treatment strategy. Chronic pain must be differentiated from pain as a possible (early) symptom of an acute disease exacerbation, classified in more detail and individually treated. These include central neuropathic pain, pain associated with spasticity, musculoskeletal pain due to excess loading and pain as a side effect of immunotherapy and in the context of comorbidities. The treatment strategies are often insufficiently evidence-based due to the lack of data.

Entities:  

Keywords:  Central neuropathic pain; Headache; Myelin-oligodendrocyte glycoprotein antibodies; Spasticity; Trigeminal neuralgia

Mesh:

Substances:

Year:  2021        PMID: 34032887     DOI: 10.1007/s00482-021-00554-5

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  29 in total

1.  Foveal changes in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder are independent of optic neuritis and not overtly progressive.

Authors:  Adriana Roca-Fernández; Frederike Cosima Oertel; Tianrong Yeo; Seyedamirhosein Motamedi; Fay Probert; Matthew J Craner; Jaume Sastre-Garriga; Hanna G Zimmermann; Susanna Asseyer; Joseph Kuchling; Judith Bellmann-Strobl; Klemens Ruprecht; Maria Isabel Leite; Friedemann Paul; Alexander Ulrich Brandt; Jacqueline Palace
Journal:  Eur J Neurol       Date:  2021-02-06       Impact factor: 6.089

2.  Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry.

Authors:  Paulus Stefan Rommer; Kerstin Eichstädt; David Ellenberger; Peter Flachenecker; Tim Friede; Judith Haas; Christoph Kleinschnitz; Dieter Pöhlau; Otto Rienhoff; Alexander Stahmann; Uwe Klaus Zettl
Journal:  Mult Scler       Date:  2018-09-19       Impact factor: 6.312

3.  Systematic assessment and characterization of chronic pain in multiple sclerosis patients.

Authors:  Diana Ferraro; Domenico Plantone; Franca Morselli; Giulia Dallari; Anna M Simone; Francesca Vitetta; Patrizia Sola; Guido Primiano; Viviana Nociti; Matteo Pardini; Massimiliano Mirabella; Catello Vollono
Journal:  Neurol Sci       Date:  2017-12-09       Impact factor: 3.307

4.  Sensory function and quality of life in patients with multiple sclerosis and pain.

Authors:  Kristina Bacher Svendsen; Troels Staehelin Jensen; Hans Jacob Hansen; Flemming Winther Bach
Journal:  Pain       Date:  2005-04       Impact factor: 6.961

Review 5.  Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.

Authors:  Susana Otero-Romero; Jaume Sastre-Garriga; Giancarlo Comi; Hans-Peter Hartung; Per Soelberg Sørensen; Alan J Thompson; Patrick Vermersch; Ralf Gold; Xavier Montalban
Journal:  Mult Scler       Date:  2016-05-19       Impact factor: 6.312

6.  Longitudinal prevalence and determinants of pain in multiple sclerosis: results from the German National Multiple Sclerosis Cohort study.

Authors:  Henrik Heitmann; Bernhard Haller; Laura Tiemann; Mark Mühlau; Achim Berthele; Thomas R Tölle; Anke Salmen; Björn Ambrosius; Antonios Bayas; Susanna Asseyer; Hans-Peter Hartung; Christoph Heesen; Martin Stangel; Brigitte Wildemann; Sarah Haars; Sergiu Groppa; Felix Luessi; Tania Kümpfel; Sandra Nischwitz; Sven G Meuth; Luisa Klotz; Ralf A Linker; Uwe K Zettl; Ulf Ziemann; Hayrettin Tumani; Björn Tackenberg; Frauke Zipp; Heinz Wiendl; Ralf Gold; Bernhard Hemmer; Markus Ploner
Journal:  Pain       Date:  2020-04       Impact factor: 6.961

7.  Association of neuromyelitis optica with severe and intractable pain.

Authors:  Peiqing Qian; Samantha Lancia; Enrique Alvarez; Eric C Klawiter; Anne H Cross; Robert T Naismith
Journal:  Arch Neurol       Date:  2012-11

Review 8.  A mechanism-based classification of pain in multiple sclerosis.

Authors:  A Truini; P Barbanti; C Pozzilli; G Cruccu
Journal:  J Neurol       Date:  2012-07-04       Impact factor: 4.849

9.  The major brain endocannabinoid 2-AG controls neuropathic pain and mechanical hyperalgesia in patients with neuromyelitis optica.

Authors:  Hannah L Pellkofer; Joachim Havla; Daniela Hauer; Gustav Schelling; Shahnaz C Azad; Tania Kuempfel; Walter Magerl; Volker Huge
Journal:  PLoS One       Date:  2013-08-09       Impact factor: 3.240

Review 10.  Neuropathic pain: an updated grading system for research and clinical practice.

Authors:  Nanna B Finnerup; Simon Haroutounian; Peter Kamerman; Ralf Baron; David L H Bennett; Didier Bouhassira; Giorgio Cruccu; Roy Freeman; Per Hansson; Turo Nurmikko; Srinivasa N Raja; Andrew S C Rice; Jordi Serra; Blair H Smith; Rolf-Detlef Treede; Troels S Jensen
Journal:  Pain       Date:  2016-08       Impact factor: 7.926

View more
  2 in total

1.  Association of Pain with Plasma C5a in Patients with Neuromyelitis Optica Spectrum Disorders During Remission.

Authors:  Yanping Tong; Jie Liu; Tao Yang; Jingwen Wang; Tianyou Zhao; Yuezhi Kang; Yongping Fan
Journal:  Neuropsychiatr Dis Treat       Date:  2022-05-17       Impact factor: 2.989

Review 2.  Corneal Confocal Microscopy to Image Small Nerve Fiber Degeneration: Ophthalmology Meets Neurology.

Authors:  Ioannis N Petropoulos; Gulfidan Bitirgen; Maryam Ferdousi; Alise Kalteniece; Shazli Azmi; Luca D'Onofrio; Sze Hway Lim; Georgios Ponirakis; Adnan Khan; Hoda Gad; Ibrahim Mohammed; Yacob E Mohammadi; Ayesha Malik; David Gosal; Christopher Kobylecki; Monty Silverdale; Handrean Soran; Uazman Alam; Rayaz A Malik
Journal:  Front Pain Res (Lausanne)       Date:  2021-08-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.